Loargys Injection
NDC 81583-105
Product Information
Loargys (pegzilarginase-nbln) is a BLA-approved product labeled by Immedica Pharma Us Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection for intravenous; subcutaneous administration. This product entry covers the primary NDC 81583-105 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 81583-105?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PEGZILARGINASE (UNII: 4YV4KW88GD)
- PEGZILARGINASE (UNII: 4YV4KW88GD) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- GLYCERIN (UNII: PDC6A3C0OX)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- MONOBASIC POTASSIUM PHOSPHATE (UNII: 4J9FJ0HL51)
- DIBASIC POTASSIUM PHOSPHATE (UNII: CI71S98N1Z)
- WATER (UNII: 059QF0KO0R)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2738655 - pegzilarginase-nbln 5 MG in 1 ML Injection
- RxCUI: 2738655 - 1 ML pegzilarginase-nbln 5 MG/ML Injection
- RxCUI: 2738655 - pegzilarginase-nbln 5 MG per 1 ML Injection
- RxCUI: 2738655 - pegzilarginase-nbln 5 MG/ML per 1 ML Injection
- RxCUI: 2738662 - Loargys 5 MG in 1 ML Injection
* Please review the full disclaimer at the bottom of this page.